论文部分内容阅读
目的探讨临床药学监护及合理用药分析在支气管哮喘治疗中的应用效果。方法选取2013年1月—2015年1月万载县株潭中心卫生院收治的68例支气管哮喘患者,按照随机双盲法分为对照组与研究组,各34例。对照组患者予以常规药物治疗,研究组在常规药物治疗的基础上针对疾病实施药学监护,并进一步分析药物应用的合理性。比较两组患者的临床疗效、治疗前后肺功能指标〔第1秒用力呼气末容积(FEV1)、第1秒用力呼气末容积与用力肺活量比值(FEV1/FVC)以及呼气峰流速(PEF)〕、住院时间、治疗依从性以及药物不良反应发生情况。结果治疗时研究组患者应用的药物种类较多,主要包括头孢唑肟、特布他林、茶碱缓释片以及二羟丙茶碱等。研究组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者FEV1、FEV1/FVC、PEF比较,差异无统计学意义(P>0.05);治疗后研究组患者FEV1、FEV1/FVC、PEF高于对照组,差异有统计学意义(P<0.05)。研究组患者住院时间短于对照组,治疗后服药依从性量表(Morisky)评分低于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论临床药学监护及合理用药分析在支气管哮喘治疗中应用效果明显,可有效提高患者临床症状的控制率,改善肺功能指标,提高治疗依从性,且不良反应少。
Objective To investigate the clinical effects of clinical pharmacy monitoring and rational drug use in the treatment of bronchial asthma. Methods Sixty-eight patients with bronchial asthma who were admitted to Zhuzhou Central Hospital of Wanzai from January 2013 to January 2015 were randomly divided into control group and study group with 34 cases in each group. Patients in the control group were treated with conventional drugs. The research group conducted the pharmacy monitoring on the basis of the conventional drug therapy and further analyzed the rationality of the drug application. The clinical efficacy of the two groups were compared before and after treatment, lung function indexes (FEV1, FEV1 / FVC and peak expiratory flow rate (PEF )], Length of stay, treatment adherence, and adverse drug reactions. Results The patients in the study group were treated with more kinds of drugs, including ceftizoxime, terbutaline, theophylline sustained-release tablets and diprophylline. The total effective rate of the study group was higher than that of the control group, the difference was statistically significant (P <0.05). There was no significant difference in FEV1, FEV1 / FVC and PEF between the two groups before treatment (P> 0.05). After treatment, FEV1, FEV1 / FVC and PEF in study group were higher than those in control group (P < 0.05). The hospitalization time of study group was shorter than that of control group. Morisky score was lower than that of control group after treatment, and the incidence of adverse reactions was lower than that of control group (P <0.05). Conclusion Clinical pharmacy monitoring and rational use of drug analysis in the treatment of bronchial asthma obvious effect, which can effectively improve the clinical symptoms of patients with control, improve lung function, improve treatment compliance, and fewer adverse reactions.